Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
HighStrong financials and growth story over the years
Profitability
HighShowing good signs of profitability & efficiency
Entry point
BadThe stock is in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
—
—
—
Beryl Drugs is engaged in the manufacturing of allopathic pharmaceuticals preparations.
Customise key metrics, see detailed forecasts, download stock data and more
Pledged promoter holdings is insignificant
In last 3 months, mutual fund holding of the company has almost stayed constant
BERYL DRUGS LTD. - 524606 - Board Meeting Intimation for TO CONSIDER AND APPROVE THE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH SEPTEMBER, 2023 | Download
BERYL DRUGS LTD. - 524606 - Board Meeting Intimation for TO CONSIDER AND APPROVE THE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH SEPTEMBER, 2023 | Download
Total Promoter HoldingIncreasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant